Covid-19 Updates: Allarity Therapeutics has partnered with Northern Arizona University to evaluate the antiviral activity of our PARP inhibitor Stenoparib (2X-121) for the potential treatment of COVID-19.
Allarity Therapeutics is a clinical-stage precision medicine company actively advancing a pipeline of in-licensed oncology therapeutics for patients with difficult-to-treat cancers. The company is leveraging its proprietary, highly accurate Drug Response Predictor (DRP®) technology to refine patient selection and improve clinical outcomes. Publicly traded on the NASDAQ First North, Allarity (ALLR: SS) is headquartered in Horsholm, Denmark, with US operations, and is committed to enhancing patient outcomes through improved decision-making and personalized cancer care.
Our Pipeline
Our Platform
Our DRP® Technology is a first-in-class, highly validated diagnostic platform that models human tumor biology and can help predict whether a cancer patient will respond or not to a particular drug
Publications
Results from our DRP® platform have been published in numerous peer-reviewed scientific journals, highlighting the predictive capabilities of our proprietary approach to precision medicine.
Events
Sedermeradagen
Date: 28/09/2020
Time: 11:00am
Location: Clarion Malmö Live, Dag Hammarskjölds Torg 2, Malmö, Sweden/
Q1 2020 Conference Call
Date: 29/05/2020
Time: 5:00pm CST
Location: Online
The DRP® Platform
No two people are the same. Neither are their cancers. DRP® technology is a unique and best-in-class proprietary diagnostic platform built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types, and refined with actual gene expression data from more than 3,000 patient tumors"We are building a personalized medicine company developing new therapeutics for unmet needs in the treatment of human cancers through use of our world-class companion diagnostics platform."
Steve Carchedi, CEO
